Tag: Crohn’s Disease treatment
Johnson & Johnson’s Dual Control Campaign: A New Chapter for IBD Dreams
Johnson & Johnson’s new “Dual Control” campaign addresses the challenge many IBD patients face: balancing health management with pursuing life dreams. The campaign emphasizes deeper disease control and patient-healthcare team partnerships to help people with IBD reclaim their ambitions.
Japan’s IBD Crisis: What Rising Rates Mean for Us
New research showing a 40% increase in IBD cases in Japan offers crucial insights into environmental factors affecting our community. Here’s what this trend means for patients and families worldwide.
Why Staying Informed Could Change Your IBD Journey Forever
Living with IBD means navigating constant changes in treatment options and best practices. Staying informed isn’t just about understanding medications—it’s about becoming an empowered partner in your healthcare journey and unlocking better outcomes for your life with IBD.
New At-Home UC Treatment: Freedom from Hospital Chairs
The FDA approval of at-home Tremfya injections for UC represents more than convenience—it’s a shift toward treatment that fits your life, not the other way around. This flexibility could transform how we think about managing chronic illness.
Curcumin for IBD: Could This Golden Spice Transform Your Gut?
New research reveals curcumin’s potential for supporting gut health through anti-inflammatory effects and microbiome balance. Here’s what IBD patients should know about this promising natural compound and how to discuss it with your healthcare team.
New IBD Treatments Rise After Humira’s Patent Loss
AbbVie’s successful transition from Humira to newer IBD treatments like Skyrizi and Rinvoq offers hope for more treatment options and better outcomes. This competitive shift could mean more choices and potentially lower costs for our community.
Revolutionary TL1A Therapies Bring New Hope to IBD Patients
Multiple pharmaceutical giants are racing to develop TL1A binder therapies that could revolutionize IBD treatment by targeting inflammation in a completely new way. Early clinical trial results show promising remission and healing rates, offering genuine hope for patients who need better treatment options.
A $36 Billion Promise: What IBD Treatment Growth Means for You
The IBD treatment market is projected to grow from $25.5 billion to nearly $36 billion by the early 2030s, reflecting unprecedented investment in personalized medicine and innovative therapies. This growth represents hope for better treatment options and outcomes for the millions living with Crohn’s disease and ulcerative colitis.
Should You Stop Anti-TNF Therapy in Remission? What New Research Tells Us
New research reveals that stopping anti-TNF therapy during IBD remission may not lead to immediate relapse, but subtle inflammatory markers suggest the disease might still be active beneath the surface. This has important implications for treatment decisions and long-term outcomes.
New Oral Crohn’s Therapy Shows Promise in Early Research
Trethera Corporation has developed TRE-515, an oral Crohn’s medication that targets specific immune cells while preserving overall immune function. The NIH has awarded $1.8 million to advance this promising research that could revolutionize how we treat inflammatory bowel disease.
